Zentalis Pharmaceuticals Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
3.7%projected annual EPS growth
Analyst Coverage
9analysts covering
FY EPS (est.)
-$1.67next fiscal year
Reporting Calendar
| Event | Expected Date |
|---|---|
| DENALI Part 2 Topline Readout | 31 Dec 2026 |
Monitoring Framework
Key Performance Indicators
Cash, Cash Equivalents, and Marketable Securities Quarterly211.8MTarget: Sufficient to fund operations into late 2027
Quarterly Research and Development (R&D) Expenses Quarterly28.7MTarget: Manageable clinical trial spend
Watch Items
- DENALI Part 2 Topline ReadoutTrigger: Topline data release by year-end 2026Action: Evaluate efficacy (ORR) and safety profile to support potential accelerated approval filing with the FDA.
- ASPENOVA Phase 3 Trial EnrollmentTrigger: Enrollment of approximately 420 patientsAction: Monitor recruitment rate and execution of the randomized confirmatory trial comparing azenosertib to standard-of-care chemotherapy.
Research as of 19 Jun 2026